Navigation Links
Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
Date:7/15/2008

Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard

Treatment, According to a New Report from Decision Resources

WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's long-term efficacy in preventing recurrence of depressive mood episodes in patients who suffer from major depressive disorder, is the attribute that most influences psychiatrists' prescribing decisions in the treatment of this disorder. Clinical data and expert opinion show that current and emerging therapies will continue to struggle for patient share through subtle differences in efficacy, tolerability and delivery.

The new report entitled Major Depressive Disorder: Long-Term Efficacy Would Differentiate a New Drug in the Crowded Antidepressant Market finds that if an agent preventing recurrence of depressive mood episodes superior to that of sales-leading Wyeth's Effexor XR were to be launched, it would earn a 25 percent patient share, according to surveyed psychiatrists. The report also finds that although Effexor XR is the sales leader in the major depressive disorder drug market, the current and future Decision Resources proprietary clinical gold standard treatment for the indication is escitalopram (Lundbeck's Cipralex/Seroplex; Forest's Lexapro).

Although escitalopram's efficacy is not the highest in our study, the drug outscored any other current therapy in the area of safety. Experts we interviewed explain that because the drug is an active metabolite, lower doses can be used, an advantage that results in safety benefits.

"Based on available data and expert opinion, we do not expect any therapy under development to displace escitalopram as the clinical gold standard for major depressive disorder," said Carlos Dedesma, Ph.D., analyst at Decision Resources. "Although some therapies in development hold pr
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease
2. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
3. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
4. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
5. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
10. Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
11. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Kindred Hospital Houston Northwest, with Wound Care Specialists, ... new outpatient wound healing center.  The wound healing ... hard to heal wounds. Chronic wounds include diabetic ... leg wounds related to blood flow issues, post-surgical ... wounds which are complex and demonstrate delayed healing. ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... MOUNTAIN VIEW, Calif., Jan. 4, 2011 PneumRx, Inc. ... bringing innovation and improvements to the treatment of lung ... in working capital commitments.  The oversubscribed round was led ... both leading venture capital firms from Europe, and also ...
... CITY, Calif., Jan. 4, 2011 Arstasis is pleased ... to physicians, nurses, patients, and cath lab technicians across ... of physicians participating in Arstasis clinical trials and select ...  As of today, the company is making the simple-to-use, ...
Cached Medicine Technology:PneumRx, Inc. Raises $33 Million in Capital 2PneumRx, Inc. Raises $33 Million in Capital 3Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants 2
(Date:7/11/2014)... 11, 2014 As part of ... Liebhard LLP has been closely monitoring the ongoing ... (FDA) Obstetrics and Gynecology Devices Panel, which ... the cancer risks associated with the use of ... to a report published by Dow Jones Business ...
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... Supplements, Specialty Nutrients, Animal Feed), Applications (Regular, Therapeutic, ... - Global Trends & Forecasts to 2019 ” ... an analysis and forecasting of the market value ... identifies the driving and restraining factors for the ...
(Date:7/11/2014)... disposable medical suppliers call for the biggest share of ... past two decades, the world market for disposable medical ... year), primarily owing to the importance of these products ... market for disposable medical supplies in the world, accounting ... held by Europe with a 29% market share. The ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... five years to 2014 on the heels of fresh ... prompted farmers to dedicate a larger share of their ... More specifically, the regulations required the mixing of 5.0% ... biofuel production in the United States created a key ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3
... draws attention to urgency in preventing stroke and supporting 6 million stroke ... ... This year nearly 795,000 people will have a stroke, leaving a path ... to National Stroke Association , which is observing National Stroke Awareness ...
... Everywhere, Inc. filed a federal complaint today seeking an injunction against the ... ... Everywhere, Inc . filed a federal complaint today seeking an injunction against ... import of Electronic Cigarettes. The company believes the use of inhaled nicotine ...
... provide telephone based triage and health advice to EosHealth service ... As EosHealth subscribers manage their health through interactive resources via ... health triggers and proactively reach out to perform triage and ... ...
... in Alzheimer,s disease, people become less efficient at separating ... found. , Knowing this, clinicians may be able ... to remember high-value information better, according to a report ... by the American Psychological Association. , Remembering what,s ...
... PARK, Calif., May 4 Acclarent, Inc., the pioneer ... the treatment of chronic sinusitis, announced today that the ... 7,500,971, entitled "Devices, Systems and Methods for Treating Disorders ... This patent and Acclarent,s earlier 7,462,175 patent are ...
... Steps to Prevent Spreading FluNORRISTOWN, Pa., May 3 ... first laboratory-confirmed case of 2009 A/H1N1 in a 31-year-old ... confirmed case, it is even more important for the ... can help prevent the spread of the flu," said ...
Cached Medicine News:Health News:Four of Five Families Will Be Touched by Stroke in 2009 2Health News:Press Release: Electronic Cigarette VS FDA 2Health News:SironaHealth to Provide 24 x 7 Nurse Line and Clinical Outreach to EosHealth as part of their Mobile Health & Wellness Programs 2Health News:SironaHealth to Provide 24 x 7 Nurse Line and Clinical Outreach to EosHealth as part of their Mobile Health & Wellness Programs 3Health News:Memory grows less efficient very early in Alzheimer's disease 2Health News:Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies 2Health News:Governor Rendell Announces Pennsylvania's First Confirmed Case of 2009 A/H1N1 Flu 2Health News:Governor Rendell Announces Pennsylvania's First Confirmed Case of 2009 A/H1N1 Flu 3
For the qualitative detection of group A Streptococcal antigen from throat swabs...
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine or serum specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
Medicine Products: